Iran vs Kyrgyzstan: The number of people with susceptibility test result for rifampicin
Iran
1,828
in 2021
Kyrgyzstan
1,932
in 2021
Iran rank
51st
Kyrgyzstan rank
49th
The number of people with susceptibility test result for rifampicin over time
- Iran
- Kyrgyzstan
How they compare
Kyrgyzstan currently reports 1,932 against 1,828 in Iran, a difference of 104.
That makes Kyrgyzstan's figure about 1.1 times Iran's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Iran ahead.
Iran ranks 51st and Kyrgyzstan ranks 49th of 155 countries.
Across the 2 decades both report, Iran averaged higher in 1 and Kyrgyzstan in 1.
Head to head by decade
| Decade | Iran | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,008 | 2,316 | 692.33 | Iran |
| 2020s | 1,608 | 1,836 | 229 | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Iran or Kyrgyzstan?
- Kyrgyzstan, at 1,932 against 1,828 in Iran as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Iran and Kyrgyzstan?
- 104, with Kyrgyzstan ahead.
- How many years of comparable data are there for Iran and Kyrgyzstan?
- 5 years are reported by both, from 2017 to 2021.
- How do Iran and Kyrgyzstan rank globally for the number of people with susceptibility test result for rifampicin?
- Iran ranks 51st and Kyrgyzstan ranks 49th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.